(Total Views: 376)
Posted On: 06/04/2025 5:31:52 PM
Post# of 154604
Tecentrig, Roche's cancer immunotheraphy, is facing a "patent cliff"...as it's key US patent expires in 2028.
To mitigate this, Roche is developing and launching a subcutaneous (SC) formulation of Tecentriq.
Any of this sound familiar?
To mitigate this, Roche is developing and launching a subcutaneous (SC) formulation of Tecentriq.
Any of this sound familiar?
(2)
(0)
